0001209191-17-040978.txt : 20170619 0001209191-17-040978.hdr.sgml : 20170619 20170619211751 ACCESSION NUMBER: 0001209191-17-040978 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170615 FILED AS OF DATE: 20170619 DATE AS OF CHANGE: 20170619 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: OncoCyte Corp CENTRAL INDEX KEY: 0001642380 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 271041563 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1010 ATLANTIC AVENUE STREET 2: SUITE 102 CITY: ALAMEDA STATE: CA ZIP: 94501 BUSINESS PHONE: 510-775-0515 MAIL ADDRESS: STREET 1: 1010 ATLANTIC AVENUE STREET 2: SUITE 102 CITY: ALAMEDA STATE: CA ZIP: 94501 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BAILEY DON M CENTRAL INDEX KEY: 0001223697 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37648 FILM NUMBER: 17919714 MAIL ADDRESS: STREET 1: 1300 N. KELLOGG DRIVE STREET 2: SUITE D CITY: ANAHEIM STATE: CA ZIP: 92607 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2017-06-15 0 0001642380 OncoCyte Corp OCX 0001223697 BAILEY DON M C/O ONCOCYTE CORPORATION 1010 ATLANTIC AVENUE, SUITE 102 ALAMEDA CA 94501 1 0 0 0 Common Stock 247001 D Option to Purchase Common Stock 5.10 2017-06-15 4 A 0 6520 0.00 A 2027-06-14 Common Stock 6520 6520 D Option to Purchase Common Stock 5.10 2017-06-15 4 A 0 20000 0.00 A 2027-06-14 Common Stock 20000 20000 D The shares are held by Mr. Bailey and his wife as co-trustees of a revocable trust, and in such capacity Mr. Bailey and his wife have shared voting and dispositive power over the shares. Options are granted to directors annually. These options are a "transitional grant" reflecting the change in the date of the annual grant from February to the date of the annual meeting of shareholders. The options are 32.60% of the annual grant for the 119-day gap between February 16, 2017, one year from the last annual grant, and June 15, 2017, date of the full annual grant for 2017-2018. Will become exercisable in four equal installments on September 30, 2017, December 31, 2017, March 31, 2018, and one day before the Company's next annual meeting of shareholders, based upon continued service on the board of directors from the date of grant on June 15, 2017. /s/Don M. Bailey 2017-06-19